NYSEAMERICAN: $ATNM Advancing the Future of Targeted Radiotherapy Actinium Pharmaceuticals has recently shared significant updates regarding its lead program, Actimab-A, an antibody-radioisotope conjugate (ARC) designed to treat high-risk acute myeloid leukemia (AML). These developments mark a pivotal moment for the company’s clinical and commercial strategies. Intellectual Property and Manufacturing Success The company confirmed robust progress…